GlycoMimetics Inc (NASDAQ: GLYC) is -8.47% lower on its value in year-to-date trading and has touched a low of $1.11 and a high of $3.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GLYC stock was last observed hovering at around $2.28 in the last trading session, with the day’s loss setting it -0.12%.
Currently trading at $2.16, the stock is -20.36% and -24.32% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing -5.26% at the moment leaves the stock 4.58% off its SMA200. GLYC registered 44.00% gain for a year compared to 6-month gain of 53.19%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -26.28% loss in the last 1 month and extending the period to 3 months gives it a -29.41%, and is -13.77% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.85% over the week and 8.30% over the month.
GlycoMimetics Inc (GLYC) has around 35 employees, a market worth around $139.21M and $0.01M in sales. Profit margin for the company is -368997.80%. Distance from 52-week low is 94.59% and -38.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-95.89%).
The EPS is expected to shrink by -5.17% this year
The shares outstanding are 64.39M, and float is at 58.36M with Short Float at 2.73%.
GlycoMimetics Inc (GLYC) Insider Activity
The most recent transaction is an insider purchase by Rock Edwin, the company’s Chief Medical Officer. SEC filings show that Rock Edwin bought 30,403 shares of the company’s common stock on Sep 22 ’23 at a price of $1.38 per share for a total of $41956.0. Following the purchase, the insider now owns 0.38 million shares.
GlycoMimetics Inc disclosed in a document filed with the SEC on Sep 21 ’23 that Rock Edwin (Chief Medical Officer) bought a total of 35,000 shares of the company’s common stock. The trade occurred on Sep 21 ’23 and was made at $1.38 per share for $48300.0. Following the transaction, the insider now directly holds 0.34 million shares of the GLYC stock.
Still, SEC filings show that on May 17 ’23, Hahn Brian M. (SVP Finance, CFO) disposed off 3,700 shares at an average price of $1.95 for $7215.0. The insider now directly holds 53,143 shares of GlycoMimetics Inc (GLYC).
